PsyMed Ventures

PsyMed Ventures is a venture capital firm focused on transforming mental health treatment through innovative technologies, particularly in the areas of psychedelic medicine, neurotechnology, and precision psychiatry. Founded in 2020 by Dina Burkitbayeva, Greg Kubin, and Matias Serebrinsky, PsyMed Ventures began as a syndicate and has since evolved into a dedicated venture fund. In 2022, the firm launched a $25 million fund aimed at supporting early-stage startups that are pioneering new approaches to mental health. The fund's investments span a range of groundbreaking companies, including Freedom Biosciences and Delix Therapeutics, both of which are exploring the therapeutic potential of psychedelics. PsyMed's portfolio also includes companies working on advanced digital health platforms, novel drug formulations, and innovative neurotechnologies. PsyMed Ventures is particularly interested in companies at the pre-seed, seed, and Series A stages, believing that these early phases are where they can make the most significant impact. The firm emphasizes the importance of aligning with values-driven investors and entrepreneurs, recognizing that the mental health space requires long-term commitment and a collaborative approach.